Dabrafenib plus trametinib in BRAF V600E-mutant Erdheim-Chester disease: a case series including CNS involvement. (PubMed, Int J Hematol) - Sep 28, 2026 - "This case series highlights the effectiveness and tolerability of dabrafenib plus trametinib for BRAF V600E-mutant ECD, including cases with CNS and cardiovascular involvement. Molecular diagnosis and targeted therapy appear to be critical for optimizing outcomes, although further prospective studies are warranted to clarify the long-term effectiveness, resistance mechanisms, and optimal duration of this treatment approach."
Journal • Cardiovascular • CNS Disorders • Langerhans Cell Histiocytosis • Rare Diseases • BRAF • CD1a • CD68
|
|
Akira Honda; Hirofumi Takano; Mariko Tanaka; Mineo Kurokawa; Mitsuhiro Yuasa; Munetoshi Hinata; Shuhei Matsumoto; Takayuki Tsujimoto; Teruaki Yamaguchi; Yuya Kurihara
|